<DOC>
	<DOCNO>NCT01001208</DOCNO>
	<brief_summary>The purpose study evaluate efficacy add methotrexate etanercept compare etanercept monotherapy measure percentage participant achieve 75 % improvement baseline Psoriasis Area Severity Index ( PASI 75 ) Week 24 .</brief_summary>
	<brief_title>The Efficacy Safety Adding Methotrexate Etanercept Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Is capable understand give write , voluntary inform consent study screen Male female ≥18 year age time screening Has stable moderate severe plaque psoriasis least 6 month ( eg , morphology change significant flare disease activity ) Has involve body surface area ( BSA ) ≥ 10 % Psoriasis Area Severity Index ( PASI ) ≥ 10 screen baseline Is candidate systemic therapy phototherapy opinion investigator Has negative test hepatitis B surface antigen hepatitis C antibody Has negative purify protein derivative test within 30 day prior first IP dose . Tuberculin skin test consider positive great equal 5 mm induration 4872 hour test place . Patients positive tuberculin skin test ( less equal 14 mm induration ) allow history Bacillus CalmetteGuerin vaccination negative Quantiferon test past year , symptom per tuberculosis worksheet , negative chest X ray . Has negative serum pregnancy test within 28 day initiate Investigational Product ( IP ) negative urine pregnancy test baseline female ( except least 3 year post menopausal surgically sterile ) Females willing use highly effective form birth control ( decide upon investigator ) study 3 month end treatment ( except woman least 3 year post menopausal surgically sterile ) Males willing use highly effective form birth control ( decide upon investigator ) study 5 month end treatment ( except men surgically sterile whose female partner least 3 year post menopausal , surgically sterile , use highly effective form birth control ) Men pregnant female partner willing use effective method ( decide upon investigator ) ensure unborn child expose IP via semen Patient designee must ability inject etanercept subcutaneously Skindisease relate Has active guttate , erythrodermic , pustular psoriasis time screen visit . Has evidence skin condition time screen visit ( eg , eczema ) would interfere evaluation effect IP psoriasis . Medical condition Has significant concurrent medical condition , include : Type 1 diabetes Poorly control type 2 diabetes ( hemoglobin A1c &gt; 8.5 ) Symptomatic heart failure ( New York Heart Association [ NYHA ] class II , III , IV ) Myocardial infarction within last year Current history unstable angina pectoris within last year Uncontrolled hypertension define rest blood pressure ≥ 160/95 mmHg prior randomization ( confirm repeat assessment ) Severe chronic pulmonary disease ( eg , require oxygen therapy ) No major chronic inflammatory disease connective tissue disease psoriasis and/or psoriatic arthritis Multiple sclerosis demyelinate disease Active malignancy , include evidence cutaneous basal squamous cell carcinoma melanoma , history cancer ( fully resect surgically cure cutaneous basal cell squamous cell carcinoma ) within 5 year first IP dose . If malignancy occur 5 year ago , documentation diseasefree state since treatment require . Known immunodeficiency syndrome include human immunodeficiency virus ( HIV ) Uncontrolled , clinically significant history renal disease Alcoholic hepatitis Any condition , opinion investigator , might cause study detrimental patient Has active CTC grade 2 high infection ( include chronic localized infection ) within 30 day prior screen , screen , screen period prior first investigational product ( IP ) dose Is pregnant breast feeding Has condition could , opinion investigator , compromise patient 's ability give write consent and/or comply study procedure , history substance abuse psychiatric condition Methotrexate contraindication precaution Has family history heritable liver disease ( eg , hemachromatosis , Wilson 's disease ) Has history evidence screen baseline alcohol abuse , alcoholic liver disease , clinically significant liver disease Is unwilling unable limit alcohol consumption 24week trial period ( allowable limit : 4 drink week , 2 drink single day . 1 drink = 1 ( 5 oz ) glass wine = 1.5 oz liquor = 12 oz beer hard cider ) Has estimate total cumulative methotrexate exposure ( medical history ) exceed 1000 mg , unless subsequent liver biopsy demonstrate grade IIIb great injury Has history significant methotrexate toxicity include pneumonitis significant cytopenias Laboratory abnormality Has laboratory abnormality screen , include : Aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; upper limit normal ( screen fail abnormal AST/ALT , 1 repeat measurement allow ) Serum total bilirubin ≥ 1.5 mg/dL Abnormal serum albumin ( &lt; 3.5 g/dL ) Hemoglobin &lt; 11 g/dL Platelet count &lt; 125,000 /mm^3 White blood cell count &lt; 3,500 cells/mm^3 Absolute neutrophil count &lt; 1500/mm^3 Estimated creatinine clearance &lt; 50 mL/min ( CockroftGault formula , calculate value provide site ) Any laboratory abnormality , , opinion investigator , prevent patient complete study interfere interpretation study result Washouts disallow medication Has use follow therapy within 14 day IP initiation : Ultraviolet light B therapy Topical cyclosporine calcineurin inhibitor Topical vitamin A D analog preparation Class III VII topical steroid ( exception : permitted scalp , axilla , groin ) Has use follow therapy within 28 day IP initiation : Intravenous oral calcineurin inhibitor Ultraviolet light A therapy Psoralen ultraviolet light A therapy Oral retinoids Class I II topical steroid Anthralin Any systemic psoriasis therapy ( eg , cyclosporine ) , include oral parenteral corticosteroid Cyclophosphamide Sulfasalazine Has use methotrexate within 28 day IP initiation . Patients prior use methotrexate must exclude subject discontinue clinically significant adverse event ( eg , severe skin reaction , methotrexateinduced lung disease , adverse event investigator feel might cause study detrimental patient ) Has use biologic therapy ( interleukin ( IL ) 12/IL23 inhibitor antitimor necrosis factor ( TNF ) agent ) within 3 month IP initiation Has use IL12/23 inhibitor within 6 month IP initiation ( eg , CNTO 1275 , ABT 874 ) Has use one antiTNF agent ( eg , etanercept , adalimumab , infliximab ) within 3 month IP initiation . Patients prior use antiTNF agent must exclude subject discontinue lack efficacy clinically significant adverse event ( eg , serious infection , neurologic event , malignancy , hematologic event , adverse event investigator feel might cause study detrimental patient ) . Has previously use efalizumab ( Raptiva® ) . Other investigational procedure exclude . currently enrol yet complete least 30 day 5 halflives ( applicable ; whichever longer ) since end investigational device drug study ( ) , receive investigational agent ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Etanercept</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Psoriasis</keyword>
</DOC>